All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The GvHD Hub was pleased to speak to Takanori Teshima, Hokkaido University, Sapporo, JP. We asked, Does using haploidentical hematopoietic stem cell transplantation (haplo-HSCT) compared with cord blood transplant impact graft-versus-host disease (GvHD) rates?
Does using haplo-HSCT compared with cord blood transplant impact GvHD rates?
Teshima begins by remarking on the increasing numbers of both haplo-HSCT and cord blood transplants in Japan. Teshima then discusses recent research that has compared haplo-HSCT and cord blood transplant outcomes in terms of acute GvHD and chronic GvHD development, as well as relapse rates, overall survival, and time taken to return to everyday life.
Teshima concludes by commenting on how a patient's risk status may determine the most appropriate treatment option.
Preventing GvHD with posttransplant cyclophosphamide combined with cyclosporin A: Results from HOVON-96
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is potentially curative for a range of hematologic malignancies; however,...
How does stem cell source impact GvHD?
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, How does stem cell source impact GvHD?
Subscribe to get the best content related to GvHD delivered to your inbox